Cancer Genetics Inc (CGIX) 7.07 $CGIX
Cancer Genetics, Inc. to Participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics & Healthcare IT Conference
GlobeNewswire - Thu Feb 12, 3:30PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that CEO and President Panna Sharma will participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th.
CGIX: 7.07 (unch)
Cancer Genetics Appoints Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management
GlobeNewswire - Wed Feb 11, 9:56AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company" , an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management. Goodman is a nationally recognized expert in value-based reimbursement and brings more than 20 years of experience from both the public and private sector in the field of health economics and healthcare policy to CGI. Goodman will be responsible for reimbursement, managed care, payer access and revenue cycle management.
CGIX: 7.07 (unch)
Cancer Genetics, Inc. Selected to Power Molecular and Biomarker Testing for Six Clinical Trials With Leading Biotech Companies Focused on Hematological Cancers
GlobeNewswire - Thu Feb 05, 10:00AM CST
-- Cancer Genetics, Inc. will provide comprehensive biomarker testing, genomic analysis and molecular information for clinical trials in multiple hematological cancers.
CGIX: 7.07 (unch)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Professor Shiloh, Israel Cancer Research Fund "Research Professor" Awarded First Olav Thon Foundation Prize
PR Newswire - Thu Jan 22, 3:00PM CST
Professor Yossi Shiloh, a recipient of the prestigious Research Professorship of the Israel Cancer Research Fund (ICRF) and the Myers Professor of Cancer Genetics at Tel Aviv University's Sackler School of Medicine, has been awarded the Olav Thon Foundation's first International Research Award for Mathematics/ Natural Sciences and Medicine for 2015. He will be sharing this honor and the $660,000 prize money with Professor Judith Campisi of the Buck Institute for Research on Aging in Berkeley, California. The ceremony will take place on March 5, 2015 at the University of Norway in Oslo.
CGIX: 7.07 (unch)
Cancer Genetics, Inc. Launches Digital Platform to Enable Collaboration With Community Hospitals and Laboratories
GlobeNewswire - Tue Jan 20, 6:30AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) ("CGI" or "the company" , an emerging leader in DNA-based cancer diagnostics, announced today the launch of their ExpandDx collaborative testing program. CGI's ExpandDx program, which utilizes VENTANA digital pathology technology from Roche, allows community-based hospitals and pathology labs to partner with CGI through remote consultations, and enables access to a broader range of tests that expand the clinical testing capabilities of community labs and hospitals. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases.
CGIX: 7.07 (unch)
Advisory Board Adds Royall to its Higher Education Lineup - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 2:20PM CST
The Advisory Board Company (ABCO) has announced the completion of its Royall & Company takeover.
BGMD: 0.88 (unch), ABCO: 53.69 (+0.32), AHS: 20.56 (-0.34), CGIX: 7.07 (unch)
Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.71 (-0.03), ATNM: 3.60 (-0.29), AKER: 3.50 (+0.20), CGIX: 7.07 (unch)
Insider Trading Alert - AMT, LNC And CGIX Traded By Insiders
at The Street - Tue Dec 16, 11:29AM CST
Stocks with insider trader activity include AMT, LNC and CGIX
AMT: 96.40 (+0.43), LNC: 58.44 (+0.38), CGIX: 7.07 (unch)
Cancer Genetics, Inc. Announces Appointment of Venkatadri Bobba to Cancer Genetics India's Board of Directors
GlobeNewswire - Tue Dec 16, 6:30AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company" , an emerging leader in DNA-based cancer diagnostics, announced today the addition of Venkatadri Bobba to Cancer Genetics India's Board of Directors.
CGIX: 7.07 (unch)
Insider Trading Alert - BYD, CGIX And AAWW Traded By Insiders
at The Street - Mon Dec 15, 10:00AM CST
Stocks with insider trader activity include BYD, CGIX and AAWW
AAWW: 48.01 (+0.44), BYD: 14.36 (-0.23), CGIX: 7.07 (unch)
Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders
at The Street - Fri Dec 12, 10:15AM CST
Stocks with insider trader activity include CGIX, NBY and BIOA
BIOA: 9.21 (+0.16), NBY: 0.56 (unch), CGIX: 7.07 (unch)
Insider Trading Alert - CDW, CGIX And RDNT Traded By Insiders
at The Street - Thu Dec 11, 12:15PM CST
Stocks with insider trader activity include CDW, CGIX and RDNT
RDNT: 8.66 (-0.11), CGIX: 7.07 (unch), CDW: 37.03 (+0.63)
Cancer Genetics (CGIX) Looks Good: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:25AM CST
Cancer Genetics (CGIX) was a big mover last session, with shares rising just over 8% on the day.
Q: 63.31 (+0.06), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38), CGIX: 7.07 (unch)
Cancer Genetics, Inc. Strengthens Clinical Trials Leadership Team With Hire of Rob Fannon as Vice President of Operations
GlobeNewswire - Wed Dec 10, 6:30AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company" , an emerging leader in DNA-based cancer diagnostics, announced today that Rob Fannon has joined the company as vice president of operations in the Raleigh/Research Triangle Park (RTP), North Carolina location. Fannon, previously with Roche Molecular's BioSpecimen Management division, brings more than 10 years of operations, client management, molecular test and panel development, and biorepository management experience to CGI.
CGIX: 7.07 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:45AM CST
BLUE: 90.70 (+0.93), SC: 22.11 (+0.38), ANV: 0.97 (-0.03), UTIW: 12.10 (+0.25), AKAO: 11.11 (-0.27), CLDN: 16.45 (-0.05), MZOR: 11.79 (+0.16), NBG: 1.61 (+0.18), TTI: 5.09 (+0.04), TPLM: 5.68 (+0.06), CGIX: 7.07 (unch), LCI: 57.78 (-0.91), SAVE: 79.32 (-0.80), PQ: 3.34 (+0.11), AFMD: 5.70 (-0.25), ENSV: 2.23 (+0.04), CTC: 0.68 (-0.09), CONN: 24.69 (-0.07), PDCE: 49.17 (+0.60), KPTI: 27.12 (-0.13)
Cancer Genetics, Inc. to Receive $530,000 Through New Jersey Technology Business Tax Program
GlobeNewswire - Tue Dec 09, 8:12AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company" , an emerging leader in DNA-based cancer diagnostics, announced today that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
CGIX: 7.07 (unch)
Cancer Genetics, Inc. Announces Launch of Targeted Next Generation Sequencing Based Panel for Chronic Lymphocytic Leukemia, Focus::CLL
GlobeNewswire - Mon Dec 08, 6:30AM CST
-- Only NGS-based panel for CLL that offers information for patient risk stratification, disease management, and treatment selection
CGIX: 7.07 (unch)
RedChip Receives Top Praise for Its Performance
GlobeNewswire - Thu Dec 04, 8:45AM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, receives top praise for its performance from its long list of distinguished microcap and small-cap clients.
CGIX: 7.07 (unch)
Cancer Genetics Inc. Announces the Appointments of Dr. Howard McLeod and Geoffrey Harris to Its Board of Directors
GlobeNewswire - Wed Dec 03, 4:41PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company" , an emerging leader in DNA-based cancer diagnostics, announced today the addition of Howard McLeod, Pharm. D., and Geoffrey Harris to the Company's Board of Directors.
CGIX: 7.07 (unch)
Cancer Genetics, Inc. to Participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics & Healthcare IT Conference
GlobeNewswire - Thu Feb 12, 3:30PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that CEO and President Panna Sharma will participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th. CGIX: 7.07 (unch)
Cancer Genetics Appoints Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management
GlobeNewswire - Wed Feb 11, 9:56AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management. Goodman is a nationally recognized expert in value-based reimbursement and brings more than 20 years of experience from both the public and private sector in the field of health economics and healthcare policy to CGI. Goodman will be responsible for reimbursement, managed care, payer access and revenue cycle management. CGIX: 7.07 (unch)
Cancer Genetics, Inc. Selected to Power Molecular and Biomarker Testing for Six Clinical Trials With Leading Biotech Companies Focused on Hematological Cancers
GlobeNewswire - Thu Feb 05, 10:00AM CST
-- Cancer Genetics, Inc. will provide comprehensive biomarker testing, genomic analysis and molecular information for clinical trials in multiple hematological cancers.
CGIX: 7.07 (unch)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Professor Shiloh, Israel Cancer Research Fund "Research Professor" Awarded First Olav Thon Foundation Prize
PR Newswire - Thu Jan 22, 3:00PM CST
Professor Yossi Shiloh, a recipient of the prestigious Research Professorship of the Israel Cancer Research Fund (ICRF) and the Myers Professor of Cancer Genetics at Tel Aviv University's Sackler School of Medicine, has been awarded the Olav Thon Foundation's first International Research Award for Mathematics/ Natural Sciences and Medicine for 2015. He will be sharing this honor and the $660,000 prize money with Professor Judith Campisi of the Buck Institute for Research on Aging in Berkeley, California. The ceremony will take place on March 5, 2015 at the University of Norway in Oslo.
CGIX: 7.07 (unch)
Cancer Genetics, Inc. Launches Digital Platform to Enable Collaboration With Community Hospitals and Laboratories
GlobeNewswire - Tue Jan 20, 6:30AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) ("CGI" or "the company"
, an emerging leader in DNA-based cancer diagnostics, announced today the launch of their ExpandDx collaborative testing program. CGI's ExpandDx program, which utilizes VENTANA digital pathology technology from Roche, allows community-based hospitals and pathology labs to partner with CGI through remote consultations, and enables access to a broader range of tests that expand the clinical testing capabilities of community labs and hospitals. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases. CGIX: 7.07 (unch)
Advisory Board Adds Royall to its Higher Education Lineup - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 2:20PM CST
The Advisory Board Company (ABCO) has announced the completion of its Royall & Company takeover.
BGMD: 0.88 (unch), ABCO: 53.69 (+0.32), AHS: 20.56 (-0.34), CGIX: 7.07 (unch)
Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT. OPXA: 0.71 (-0.03), ATNM: 3.60 (-0.29), AKER: 3.50 (+0.20), CGIX: 7.07 (unch)
Insider Trading Alert - AMT, LNC And CGIX Traded By Insiders
at The Street - Tue Dec 16, 11:29AM CST
Stocks with insider trader activity include AMT, LNC and CGIX
AMT: 96.40 (+0.43), LNC: 58.44 (+0.38), CGIX: 7.07 (unch)
Cancer Genetics, Inc. Announces Appointment of Venkatadri Bobba to Cancer Genetics India's Board of Directors
GlobeNewswire - Tue Dec 16, 6:30AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today the addition of Venkatadri Bobba to Cancer Genetics India's Board of Directors. CGIX: 7.07 (unch)
Insider Trading Alert - BYD, CGIX And AAWW Traded By Insiders
at The Street - Mon Dec 15, 10:00AM CST
Stocks with insider trader activity include BYD, CGIX and AAWW
AAWW: 48.01 (+0.44), BYD: 14.36 (-0.23), CGIX: 7.07 (unch)
Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders
at The Street - Fri Dec 12, 10:15AM CST
Stocks with insider trader activity include CGIX, NBY and BIOA
BIOA: 9.21 (+0.16), NBY: 0.56 (unch), CGIX: 7.07 (unch)
Insider Trading Alert - CDW, CGIX And RDNT Traded By Insiders
at The Street - Thu Dec 11, 12:15PM CST
Stocks with insider trader activity include CDW, CGIX and RDNT
RDNT: 8.66 (-0.11), CGIX: 7.07 (unch), CDW: 37.03 (+0.63)
Cancer Genetics (CGIX) Looks Good: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:25AM CST
Cancer Genetics (CGIX) was a big mover last session, with shares rising just over 8% on the day.
Q: 63.31 (+0.06), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38), CGIX: 7.07 (unch)
Cancer Genetics, Inc. Strengthens Clinical Trials Leadership Team With Hire of Rob Fannon as Vice President of Operations
GlobeNewswire - Wed Dec 10, 6:30AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that Rob Fannon has joined the company as vice president of operations in the Raleigh/Research Triangle Park (RTP), North Carolina location. Fannon, previously with Roche Molecular's BioSpecimen Management division, brings more than 10 years of operations, client management, molecular test and panel development, and biorepository management experience to CGI. CGIX: 7.07 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:45AM CST
BLUE: 90.70 (+0.93), SC: 22.11 (+0.38), ANV: 0.97 (-0.03), UTIW: 12.10 (+0.25), AKAO: 11.11 (-0.27), CLDN: 16.45 (-0.05), MZOR: 11.79 (+0.16), NBG: 1.61 (+0.18), TTI: 5.09 (+0.04), TPLM: 5.68 (+0.06), CGIX: 7.07 (unch), LCI: 57.78 (-0.91), SAVE: 79.32 (-0.80), PQ: 3.34 (+0.11), AFMD: 5.70 (-0.25), ENSV: 2.23 (+0.04), CTC: 0.68 (-0.09), CONN: 24.69 (-0.07), PDCE: 49.17 (+0.60), KPTI: 27.12 (-0.13)
Cancer Genetics, Inc. to Receive $530,000 Through New Jersey Technology Business Tax Program
GlobeNewswire - Tue Dec 09, 8:12AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December. CGIX: 7.07 (unch)
Cancer Genetics, Inc. Announces Launch of Targeted Next Generation Sequencing Based Panel for Chronic Lymphocytic Leukemia, Focus::CLL
GlobeNewswire - Mon Dec 08, 6:30AM CST
-- Only NGS-based panel for CLL that offers information for patient risk stratification, disease management, and treatment selection
CGIX: 7.07 (unch)
RedChip Receives Top Praise for Its Performance
GlobeNewswire - Thu Dec 04, 8:45AM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, receives top praise for its performance from its long list of distinguished microcap and small-cap clients. CGIX: 7.07 (unch)
Cancer Genetics Inc. Announces the Appointments of Dr. Howard McLeod and Geoffrey Harris to Its Board of Directors
GlobeNewswire - Wed Dec 03, 4:41PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based cancer diagnostics, announced today the addition of Howard McLeod, Pharm. D., and Geoffrey Harris to the Company's Board of Directors. CGIX: 7.07 (unch)
